Hunan Jingfeng Pharmaceutical (000908) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hunan Jingfeng Pharmaceutical (000908) has a cash flow conversion efficiency ratio of -3.332x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥125.78 Million ≈ $18.41 Million USD) by net assets (CN¥-37.76 Million ≈ $-5.52 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 000908 equity to assets ratio to measure how much of total assets are equity-financed.
Hunan Jingfeng Pharmaceutical - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Hunan Jingfeng Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 000908 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Hunan Jingfeng Pharmaceutical Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hunan Jingfeng Pharmaceutical ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Minglida Precision Technology Co. Ltd.
SHE:301268
|
N/A |
|
Global Top E Commerce Co Ltd
SHE:002640
|
-0.326x |
|
MBK Public Company Limited
BK:MBK-R
|
0.028x |
|
Alerus Financial Corp
NASDAQ:ALRS
|
0.048x |
|
Cementos Pacasmayo S.A.A
F:EPCC
|
0.032x |
|
Anteris Technologies Global Corp
AU:AVR
|
-5.434x |
|
TTET Union Corp
TW:1232
|
0.042x |
|
Mid Penn Bancorp
NASDAQ:MPB
|
0.032x |
Annual Cash Flow Conversion Efficiency for Hunan Jingfeng Pharmaceutical (1999–2024)
The table below shows the annual cash flow conversion efficiency of Hunan Jingfeng Pharmaceutical from 1999 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Hunan Jingfeng Pharmaceutical worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥-15.13 Million ≈ $-2.21 Million |
CN¥-5.55 Million ≈ $-812.28K |
0.367x | +260.81% |
| 2023-12-31 | CN¥-153.68 Million ≈ $-22.49 Million |
CN¥35.06 Million ≈ $5.13 Million |
-0.228x | -139.76% |
| 2022-12-31 | CN¥214.83 Million ≈ $31.44 Million |
CN¥123.27 Million ≈ $18.04 Million |
0.574x | +51.85% |
| 2021-12-31 | CN¥327.73 Million ≈ $47.96 Million |
CN¥123.83 Million ≈ $18.12 Million |
0.378x | +188.76% |
| 2020-12-31 | CN¥638.18 Million ≈ $93.39 Million |
CN¥-271.68 Million ≈ $-39.76 Million |
-0.426x | -2385.47% |
| 2019-12-31 | CN¥1.94 Billion ≈ $284.15 Million |
CN¥36.17 Million ≈ $5.29 Million |
0.019x | -84.81% |
| 2018-12-31 | CN¥2.86 Billion ≈ $418.81 Million |
CN¥350.94 Million ≈ $51.35 Million |
0.123x | +110.21% |
| 2017-12-31 | CN¥2.60 Billion ≈ $380.45 Million |
CN¥151.65 Million ≈ $22.19 Million |
0.058x | +1136.37% |
| 2016-12-31 | CN¥2.61 Billion ≈ $382.27 Million |
CN¥12.32 Million ≈ $1.80 Million |
0.005x | -88.52% |
| 2015-12-31 | CN¥2.25 Billion ≈ $329.02 Million |
CN¥92.37 Million ≈ $13.52 Million |
0.041x | -80.17% |
| 2014-12-31 | CN¥994.04 Million ≈ $145.46 Million |
CN¥205.93 Million ≈ $30.13 Million |
0.207x | +131.95% |
| 2013-12-31 | CN¥5.31 Million ≈ $776.82K |
CN¥-3.44 Million ≈ $-503.70K |
-0.648x | -10996.71% |
| 2012-12-31 | CN¥-60.15 Million ≈ $-8.80 Million |
CN¥351.50K ≈ $51.44K |
-0.006x | +99.93% |
| 2011-12-31 | CN¥790.82K ≈ $115.72K |
CN¥-6.87 Million ≈ $-1.01 Million |
-8.689x | -3203.30% |
| 2010-12-31 | CN¥57.85 Million ≈ $8.46 Million |
CN¥-15.21 Million ≈ $-2.23 Million |
-0.263x | -122.84% |
| 2009-12-31 | CN¥100.67 Million ≈ $14.73 Million |
CN¥-11.88 Million ≈ $-1.74 Million |
-0.118x | -228.87% |
| 2008-12-31 | CN¥338.64 Million ≈ $49.55 Million |
CN¥31.02 Million ≈ $4.54 Million |
0.092x | -40.95% |
| 2007-12-31 | CN¥336.95 Million ≈ $49.31 Million |
CN¥52.26 Million ≈ $7.65 Million |
0.155x | -9.89% |
| 2006-12-31 | CN¥336.40 Million ≈ $49.23 Million |
CN¥57.90 Million ≈ $8.47 Million |
0.172x | +195.38% |
| 2005-12-31 | CN¥329.66 Million ≈ $48.24 Million |
CN¥-59.49 Million ≈ $-8.71 Million |
-0.180x | +60.83% |
| 2004-12-31 | CN¥339.45 Million ≈ $49.67 Million |
CN¥-156.37 Million ≈ $-22.88 Million |
-0.461x | -958.22% |
| 2003-12-31 | CN¥419.38 Million ≈ $61.37 Million |
CN¥22.51 Million ≈ $3.29 Million |
0.054x | +59.52% |
| 2002-12-31 | CN¥522.69 Million ≈ $76.49 Million |
CN¥17.59 Million ≈ $2.57 Million |
0.034x | -45.02% |
| 2001-12-31 | CN¥498.41 Million ≈ $72.93 Million |
CN¥30.50 Million ≈ $4.46 Million |
0.061x | +222.29% |
| 2000-12-31 | CN¥500.54 Million ≈ $73.24 Million |
CN¥-25.05 Million ≈ $-3.67 Million |
-0.050x | -278.13% |
| 1999-12-31 | CN¥485.43 Million ≈ $71.03 Million |
CN¥13.64 Million ≈ $2.00 Million |
0.028x | -- |
About Hunan Jingfeng Pharmaceutical
Hunan Jingfeng Pharmaceutical Co.,Ltd. manufactures and sells chemical drugs and biological agents in China. The company's principal product is sodium hyaluronate injection for use in orthopedics and surgery applications. It also offers ophthalmic equipment and API products, as well as engages in the research and development of antitumor, cancer, and cardiovascular drugs; and distributed in the f… Read more